Successful Placement: Revance Therapeutics

Revance Therapeutics Expands Leadership Team, Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development

NEWARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) — Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced a key addition to its leadership team with the appointment of Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development, effective immediately. Dr. Rubio will report to Chief Operating Officer Abhay Joshi, and will lead the company’s clinical development team, focusing on further accelerating the advancement of Revance’s neurotoxin development programs. Read the full release